Trump Signs Executive Order Targeting Major Cuts in U.S. Drug Prices

U.S. President Donald Trump announced a bold new policy aimed at slashing prescription drug prices in the United States by up to 80%.

In a post shared on social media Sunday, Trump revealed his intention to sign an executive order that would implement a “Most Favored Nation” pricing policy, a move he claims will finally bring fairness to American consumers.

The policy, which Trump said he would sign at 9:00 am Monday (1300 GMT), is designed to tie the price of medications sold in the U.S. to the lowest price paid for the same drug in any other country.

According to Trump, this would correct what he describes as years of unfair global pricing practices where Americans pay significantly more than people in other countries for the same treatments.

READ ALSO: Keir Starmer Pledges Tougher Immigration Controls to Rebuild Unity

“They will rise throughout the world in order to equalize and, for the first time in many years, bring FAIRNESS TO AMERICA!” Trump declared in his statement, referring to global drug prices.

The “Most Favored Nation” concept, typically used in international trade agreements to ensure equal treatment among trading partners, would now be repurposed to level the playing field in pharmaceutical pricing.

While the specifics of the policy have not yet been released, the former president’s plan appears to mark a renewed effort to take on Big Pharma — something he attempted during his first term in office from 2017 to 2021. That earlier proposal met fierce resistance from the pharmaceutical industry and ultimately stalled.

READ ALSO: Michael Saylor: First Nation to Print Its Own Currency to Buy Bitcoin Will Win the Race

Just last month, Trump signed another executive order focused on drug pricing, giving states more flexibility to seek cheaper alternatives overseas and pushing for a more competitive system to negotiate prices.

If successful, this new measure could lead to significant savings for American patients, who often face some of the highest out-of-pocket prescription costs in the developed world. However, critics argue that forcing global prices to rise could spark tensions abroad and impact the availability of medications in lower-income countries.

The White House has yet to release a detailed breakdown of the plan, and it remains to be seen how the pharmaceutical industry and international partners will respond.

Trump’s announcement has reignited the national conversation on healthcare affordability, a topic that remains a major concern for millions of Americans. As the country continues to grapple with healthcare inflation, policies like these are likely to become central to upcoming debates — both in political circles and at the pharmacy counter.